WALTHAM, Mass., Aug. 15, 2016 /PRNewswire/ -- Intervention Insights announced today that Steven W. Jones has joined the company as Chief Executive Officer and board member. Mr. Jones is responsible for shaping the company's vision and driving the growth strategy of Intervention Insights by building upon its flagship product, PrimeInsights™.
"I'm excited about Intervention Insights' position working with major health plans, pharmacy benefit managers and clinicians in transforming the molecular oncology market," says Koleman Karleski, Chairman of the Board of Directors and Managing Partner of Chrysalis Ventures. "Steven has what it takes to expand that market leadership position. He is a seasoned innovator with a proven ability to scale, and he demonstrates a rare combination of leadership, industry insight, and the ability to bring people together."
Steven Jones is a 30-year healthcare industry veteran with strategic and operational experience. He has shown strong leadership in a range of positions from large, private equity-backed companies to early-stage ventures within the life science, home infusion, and dental laboratory industries. Steven joins Intervention Insights from Dental Services Group, the largest dental laboratory network in North America, where he served as Chief Acquisition Officer. Prior to that position, he was the Division President and Executive Vice President of Business Development at CarePoint Partners, LLC, one of the largest independent home infusion companies in the nation. Mr. Jones has an MBA from Regis University and Pharmacy degree from the Medical College of Virginia.
"Steven has a thorough understanding of the need to develop and drive commercial strategies in a competitive and ever-changing molecular oncology environment," said Michael Gross, Member of the Board of Directors and Beringea's Managing Director. "As Steven leads commercial expansion efforts at Intervention Insights, I'm confident that he will continue to capitalize on the company's proven clinical approach to supporting evidence-based treatment decisions in oncology."
Precision Medicine—or treating individual patients with solutions tailored to lifestyle, biology and medical history—offers new opportunities for innovation in Molecular Oncology. Steven Jones believes Intervention Insights is in a unique position to maximize those opportunities.
"Over the past seven years, Intervention Insights has built a strong technology platform and clinically actionable knowledgebase to support clinicians, health plans, pharmacy benefit managers and laboratories," said Mr. Jones. "Precision medicine broadens the scope of how we can apply those capabilities. We are poised to expand our molecular testing and therapy utilization programs to ensure cancer patients receive the highest quality, evidence-based care."
About Intervention Insights, Inc.
Intervention Insights is a health information services company that supports evidence-based care in molecular oncology. Working in collaboration with clinicians, molecular testing laboratories and health plans, Intervention Insights has developed the PrimeInsights™ program, which is a technology-enabled service that connects physicians, payers and labs through one universal platform. PrimeInsights concisely delivers clinical evidence from peer-reviewed literature, making the latest science relevant at the point of decision-making. PrimeInsights also supports laboratories in performing comprehensive, evidence-based molecular testing and brings predictability and efficiency to authorization and reimbursement. For more information, see www.interventioninsights.com.
About Chrysalis Ventures
Chrysalis Ventures manages one of Mid-America's largest funds for early-stage and growth investments with approximately $400 million under management. Since 1993, Chrysalis Ventures has invested in 70 companies, primarily in the Healthcare and Technology sectors. Headquartered in Louisville, Kentucky, Chrysalis seeks to partner with entrepreneurs to build enduring businesses in industries undergoing significant transformation. For more information, please visit www.chrysalisventures.com.
Beringea, LLC provides equity and/or mezzanine debt to growth-oriented companies in the U.S. and UK. The Firm, which includes Michigan-based Beringea, LLC and its London, UK office Beringea LLP, invests in portfolio companies operating in a range of sectors, including health care, information technology, advanced manufacturing, media and specialized consumer products. With flexible capital solutions, extensive investing experience, and an international footprint, Beringea's team offers its portfolio companies the resources to grow their businesses and create value for stakeholders. For more information, visit www.beringea.com.
Intervention Insights, Inc.
SOURCE Intervention Insights